ATRA

Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Friday, May 3, 2024
Biotechnology, Pharmaceutical, Health, Oncology, EBV, Cancer, Epstein–Barr virus, Compensated emancipation, Patient, Employment, ATRA

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 4,150 restricted stock units of Atara’s common stock to one newly hired employee.

Key Points: 
  • Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 4,150 restricted stock units of Atara’s common stock to one newly hired employee.
  • This award was approved by the Compensation Committee of Atara’s Board of Directors and granted under the Atara Biotherapeutics, Inc. 2018 Inducement Plan, with a grant date of May 1, 2024, as an inducement material to the new employee entering into employment with Atara, in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The restricted stock units vest over four years, with 25 percent vesting on the first quarterly vesting date after the first anniversary of the vesting commencement date and the remainder vesting in 12 approximately equal quarterly installments over the following three years, subject to the employee being continuously employed by Atara as of such vesting dates.

Madison Pacific Properties Inc. announces the results for the six months ended February 29, 2024

Retrieved on: 
Saturday, April 13, 2024
MPC, CRA, International, Tax court, Comprehensive, TSX, ATRA, Tax, International Financial Reporting Standards, Canada Revenue Agency, MPP, TCC, Federal court, Life insurance

VANCOUVER, British Columbia, April 12, 2024 (GLOBE NEWSWIRE) -- Madison Pacific Properties Inc. (the Company) (TSX: MPC and MPC.C), a Vancouver-based real estate company announces the results of operations for the six months ended February 29, 2024.

Key Points: 
  • VANCOUVER, British Columbia, April 12, 2024 (GLOBE NEWSWIRE) -- Madison Pacific Properties Inc. (the Company) (TSX: MPC and MPC.C), a Vancouver-based real estate company announces the results of operations for the six months ended February 29, 2024.
  • Also included in net loss is a net gain on the fair value adjustment on investment properties of approximately $4.3 million (2023: $14.0 million).
  • The decision denied Madison Pacific Properties Inc.’s ability to use certain carryforward losses for certain taxation years within its 2009 to 2017 taxation years.
  • As at February 29, 2024, the Company owns approximately $709 million in investment properties, including the Company’s proportionate share of investment properties held through joint operations.

HighField Biopharmaceuticals Announces Two Abstracts Accepted for the 2024 ASCO Annual Meeting

Retrieved on: 
Wednesday, April 24, 2024
Biotechnology, Health, General Health, Public Relations, Investor Relations, Pharmaceutical, Oncology, Communications, Other Science, Research, Science, Clinical Trials, Cancer, Prostate, HER2, Doxorubicin, Abstract, Stomach, Breast, Tumor microenvironment, Uterus, ATRA, ASCO, Therapy, Patient, Society, Lung

HighField Biopharmaceuticals, a clinical stage immuno-oncology company using lipid-based therapeutics to treat cancer, announced today that two HighField abstracts have been accepted with one poster presentation at the American Society of Clinical Oncology (ASCO) annual meeting May 31-June 4, 2024, in Chicago, IL.

Key Points: 
  • HighField Biopharmaceuticals, a clinical stage immuno-oncology company using lipid-based therapeutics to treat cancer, announced today that two HighField abstracts have been accepted with one poster presentation at the American Society of Clinical Oncology (ASCO) annual meeting May 31-June 4, 2024, in Chicago, IL.
  • “The ASCO meeting is an important opportunity to share our unique lipid-based technology with other clinical investigators,” said Yuhong Xu, Ph.D., Founder and CEO of HighField.
  • HFK1 is a drug encapsulated immunoliposome containing doxorubicin for patients with advanced refractory solid tumors having HER2 low and HER2+ expression.
  • HF1K16 is a drug encapsulated immune modulating liposome containing all-trans retinoic acid (ATRA) for patients with recurrent and refractory glioma.

Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Friday, April 5, 2024
Biotechnology, Pharmaceutical, Health, Oncology, EBV, Epstein–Barr virus, ATRA, Patient, Employment, Cancer, Compensated emancipation

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 3,750 restricted stock units of Atara’s common stock to one newly hired employee.

Key Points: 
  • Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 3,750 restricted stock units of Atara’s common stock to one newly hired employee.
  • This award was approved by the Compensation Committee of Atara’s Board of Directors and granted under the Atara Biotherapeutics, Inc. 2018 Inducement Plan, with a grant date of April 1, 2024, as an inducement material to the new employee entering into employment with Atara, in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The restricted stock units vest over four years, with 25 percent vesting on the first quarterly vesting date after the first anniversary of the vesting commencement date and the remainder vesting in 12 approximately equal quarterly installments over the following three years, subject to the employee being continuously employed by Atara as of such vesting dates.

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress

Retrieved on: 
Thursday, March 28, 2024
Oncology, Health, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, The Lancet, Research, Graft-versus-host disease, LD, ASH, International Society, Partnership, Central nervous system, ATRA, Epstein–Barr virus, Patient, Follicular lymphoma, CNS, Biomarker, PTLD, Cancer, Lymphoproliferative disorders, SLE, EBV, NHL, Lymphoma, Mantle cell lymphoma, Investment, ATM, Safety, Pharmacokinetics, Depreciation, File, Workforce, Cell, FDA, BLA, Lupus nephritis, CD19, Food, Autoimmune disease, Pharmaceutical industry

“We are expanding Atara’s proven EBV T-cell platform into allogeneic CAR T therapy for both oncology and autoimmune disease,” said Pascal Touchon, President and Chief Executive Officer of Atara.

Key Points: 
  • “We are expanding Atara’s proven EBV T-cell platform into allogeneic CAR T therapy for both oncology and autoimmune disease,” said Pascal Touchon, President and Chief Executive Officer of Atara.
  • “This includes strong momentum for our lead CAR T program, ATA3219, which is positioned to deliver near-term clinical data for both non-Hodgkin’s lymphoma and lupus nephritis.
  • Subjects will receive lymphodepletion (LD) treatment followed by ATA3219 at a dose of 40, 80, or 160 x 106 CAR+ T cells.
  • Subjects will receive LD treatment followed by ATA3219 at a dose of 40, 80, 240, or 480 x 106 CAR+ T cells.

Atara Biotherapeutics Receives FDA Clearance of IND Application in Lupus Nephritis for ATA3219, an Allogeneic CAR T Therapy

Retrieved on: 
Thursday, February 29, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Investigational New Drug, Woman, Autoimmune disease, Physician, FDA, Food, CD19, Epstein–Barr virus, Risk, Leukapheresis, Prevalence, Safety, Lupus, Kidney, ATRA, EBV, Disease, Patient, Lupus nephritis, SLE, IND, Tissue, Mortality, Cancer

We are eager to address the significant unmet need in lupus nephritis as we initiate our Phase 1 trial,” said Pascal Touchon, President and Chief Executive Officer of Atara.

Key Points: 
  • We are eager to address the significant unmet need in lupus nephritis as we initiate our Phase 1 trial,” said Pascal Touchon, President and Chief Executive Officer of Atara.
  • Subjects will receive lymphodepletion treatment followed by ATA3219 at a dose of 40, 80, or 160 x 106 CAR+ T cells.
  • “CAR T cells can naturally infiltrate deep into target tissues to mediate B-cell depletion and produce durable responses.
  • The ATA3219 IND submission included in vitro data reflecting the CD19 antigen-specific functional activity of ATA3219 and CAR-mediated activity against B cells from SLE patients.

Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 44th Annual Health Care Conference

Retrieved on: 
Wednesday, February 28, 2024
Oncology, Health, Infectious Diseases, Genetics, Pharmaceutical, Biotechnology, PST, EST, ATRA, EBV, Conference, Epstein–Barr virus, Webcast, Patient, Cancer

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will participate in a cell therapy panel discussion at the Cowen 44th Annual Health Care Conference on Wednesday, March 6, 2024 at 6:10 a.m. PST / 9:10 a.m. EST.

Key Points: 
  • Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will participate in a cell therapy panel discussion at the Cowen 44th Annual Health Care Conference on Wednesday, March 6, 2024 at 6:10 a.m. PST / 9:10 a.m. EST.
  • A live webcast of the presentation will be available by visiting the Investors and Media section of atarabio.com .
  • An archived replay of the webcast will be available on the Company's website for 30 days following the live presentation.

Legal System Abuse Adding to Increasing Auto Insurance Costs, Creating A New Asset Class of Investors Betting on Litigation

Retrieved on: 
Tuesday, February 27, 2024
Other Automotive, Professional Services, Insurance, Automotive, Social media, Information International, Inc., Disclosure, Risk, Advertising, Insurance Information Institute, ATRA, Judgement, TPLF, MAAA, American Tort Reform Association, FCAS, IRC, Environment

Plaintiff attorneys often use aggressive marketing and advertising techniques to attract potential plaintiffs, the issues brief notes.

Key Points: 
  • Plaintiff attorneys often use aggressive marketing and advertising techniques to attract potential plaintiffs, the issues brief notes.
  • Legal system abuse in Louisiana costs every resident more than $1,100 annually, according to an analysis by the American Tort Reform Association (ATRA).
  • The state’s litigation environment was also cited by the Insurance Research Council (IRC) when reporting how Louisiana is the least affordable U.S. state for both personal auto and homeowners insurance.
  • Florida enacted new laws last year to reduce legal system abuse and to attract new insurers to replace those who departed or reduced their market share.

Atara Biotherapeutics Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus Nephritis

Retrieved on: 
Wednesday, February 14, 2024
Biotechnology, FDA, Health, Pharmaceutical, Clinical Trials, Investigational New Drug, Woman, Immune system, Autoimmune disease, Physician, Food, Technical, CD19, Epstein–Barr virus, Risk, Prevalence, Lupus, Kidney, ATRA, EBV, Phenotype, Disease, Patient, Lupus nephritis, Survival, SLE, IND, Mortality, Cancer, Vaccine

“We are dedicated to advancing medical breakthroughs with innovative cell therapies that truly make a difference.

Key Points: 
  • “We are dedicated to advancing medical breakthroughs with innovative cell therapies that truly make a difference.
  • Treatment will be facilitated for patients and physicians in avoiding apheresis and lengthy patient-by-patient manufacturing as ATA3219 would be rapidly available as an off-the-shelf treatment from finished product inventory.
  • The ATA3219 IND submission includes robust in vitro data reflecting the CD19 antigen-specific functional activity of ATA3219 and CAR-mediated activity against B cells from SLE patients.
  • Despite recent advances in treatment strategies, the response rate using existing therapies remains low, with significant risk of long-term morbidity and mortality associated with refractory LN.

Atara Biotherapeutics and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel® Data in The Lancet Oncology

Retrieved on: 
Wednesday, January 31, 2024
Biotechnology, Pharmaceutical, Health, Oncology, Rituximab, Survival, European, EBV, Graft-versus-host disease, MHRA, The Lancet, Patient, FDA, EMA, SOT, Cytokine release syndrome, Society, ATRA, ASH, HCT, Cancer, BLA, Lymphoproliferative disorders, Epstein–Barr virus

22 of 43 EBV+ PTLD patients achieved an objective response (51.2% objective response rate, or ORR).

Key Points: 
  • 22 of 43 EBV+ PTLD patients achieved an objective response (51.2% objective response rate, or ORR).
  • The median duration of response was 23.0 months and the median overall survival was 18.4 months.
  • These interim data were previously presented at the 2022 American Society of Hematology (ASH) Annual Meeting.
  • All this resonates perfectly with our purpose ‘every time we care for a single person, we make the whole world better,’” said Núria Perez-Cullell, Director of Medical Affairs, Patients & Consumers at Pierre Fabre Laboratories.